Investor Resources
Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jan 27, 2021
Company focused on continued advancement of its small molecule therapeutics platform including development of fezagepras and evaluating strategic alternatives for its plasma-derived therapeutics...
-
Jan 12, 2021
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – January 12, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company,...
-
Dec 15, 2020
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – Dec 14, 2020 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company,...
-
Dec 7, 2020
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – December 7, 2020 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company,...
-
Nov 13, 2020
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – November 13, 2020 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical...